Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 8/20 | 0.51 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200257 | 0.93 | TK1 (0.55) | TK1RNASE1TK2ALBPKM | |
| SCHEMBL23199530 | 0.84 | POLB (0.58) | TK1 | |
| SCHEMBL21787100 | 0.81 | TK1 (0.52) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL23734388 | 0.78 | RNASE1 (0.61) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL20129801 | 0.76 | RNASE1 (0.63) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL16489131 | 0.76 | RNASE1 (0.63) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL28338723 | 0.75 | TK1 (0.67) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL6224637 | 0.75 | TK1 (0.67) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL24913674 | 0.75 | RNASE1 (0.64) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL21787087 | 0.75 | TK1 (0.46) | TK1RNASE1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389049-A1 | REVERSIBLE TERMINATORS FOR DNA SEQUENCING AND METHODS OF USING THE SAME | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (VG) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389049-A1 | REVERSIBLE TERMINATORS FOR DNA SEQUENCING AND METHODS OF USING THE SAME | RNGTT, NT5C3B, NSUN2 | TK1 51/4885RNASE1 89/4885TK2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.